Roy Moore – oh fk, oh fk’in A… and Holy Shit

Wednesday, November 15, 2017

You Young People Just Don’t Get It
Back in the day, if you were creeping on a high school girl you had to call the school to track her down. There just wasn’t any other way to do it. You couldn’t find her facebook or Instagram or snapchat, you just had to call the principal’s office and try to get her on the phone. That was the only way.

A few days later, she says, she was in trigonometry class at Gadsden High when she was summoned to the principal’s office over the intercom in her classroom. She had a phone call.

“I said ‘Hello?’” Richardson recalls. “And the male on the other line said, ‘Gena, this is Roy Moore.’ I was like, ‘What?!’ He said, ‘What are you doing?’ I said, ‘I’m in trig class.’ ”

by Atrios at 21:15

Parasite Treatment Fights Prostate Cancer

Wed, 11/15/2017 – 11:43am @dddmag
by Joanne Van Zuidam – Editor –


Cancer researchers at the University of Bergen (UiB) in Norway have been experimenting with hundreds of known drugs in recent years to see how they influence cancer cells.

Their most recent discovery shows that a medication prescribed for parasites, such as tapeworms and giardia, contains a substance that kills prostate and colon cancer cells.

“We discovered that this specific substance is blocking the signaling pathway in the cancer cells, and make them stop growing. It is not often that researchers discover a substance that targets specific molecules as precisely as this one,” says Professor Karl-Henning Kalland at the department of clinical science, at UiB and leader of the research group, in a statement.

His team’s research found nitazoxanide (NTZ), an approved anti-parasitic therapy, decomposed activated Beta-catenin.

Beta-catenin is a protein found in high amounts in both prostate and colon cancer cells. The protein is critical for tumor progression–its activation not only promotes cell division but makes the cancer cells more resistant and increases their chance of survival.

The research team found that NTZ hinders the activated Beta-catenin. However, it also appears that this hindering stimulates central parts of the immune system that attacks cancer cells.

“At the moment, we are working on how to strengthen our ongoing immune therapy against prostate cancer by using the mechanisms we discovered of the NTZ,” said Kalland.

Kalland and his research team is in the first phase in a clinical trial using immune therapy against prostate cancer (cryoIT).

The study is published in Nature Chemical Biology.